Allergy and Immunology · Gilbert, AZ
NPI
1073587382
Since 2006
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4915 E Baseline Rd, Suite 112
Gilbert, AZ, 85234
Phone (480) 626-6600
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
41,979 services
Medicare patients, 2024
441
Average age 72
Drug cost, 2024
$1.6M
2,376 prescriptions
Company payments, 2025
$2,437
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sam R Shimamoto was code J2357 (injection, omalizumab, 5 mg), 22,013 times for 39 patients. In total Sam R Shimamoto billed 41,979 services in 33 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2357 Injection, omalizumab, 5 mg | Office | 22,013 | 39 | $29.74 | $655K |
| 95004 Test - Miscellaneous | Office | 3,940 | 65 | $2.51 | $9,904 |
| 95165 Treatment - Miscellaneous | Office | 2,430 | 72 | $10.29 | $25K |
| 96372 Injection Administration | Office | 1,158 | 65 | $10.63 | $12K |
| 95117 Treatment - Miscellaneous | Office | 837 | 82 | $8.00 | $6,698 |
| 99214 Office E&M - Established | Office | 593 | 301 | $91.11 | $54K |
| 99213 Office E&M - Established | Office | 192 | 146 | $60.00 | $12K |
| 94375 Pulmonary Function Testing | Office | 172 | 112 | $26.96 | $4,637 |
| 95115 Treatment - Miscellaneous | Office | 109 | 11 | $6.34 | $691 |
| 95012 Pulmonary | Office | 101 | 66 | $13.01 | $1,314 |
| 99204 Office E&M - New | Office | 58 | 58 | $116.81 | $6,775 |
| 99203 Office E&M - New | Office | 44 | 44 | $79.64 | $3,504 |
| 94060 Pulmonary Function Testing | Office | 15 | 15 | $27.83 | $417 |
By year: 2022 $543K for 22,201 services; 2023 $837K for 35,800 services; 2024 $1.0M for 41,979 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sam R Shimamoto prescribed most often to Medicare patients was Levocetirizine Dihydrochloride, with 268 prescriptions and refills. In total Sam R Shimamoto wrote 2,376 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levocetirizine Dihydrochloride Generic | 268 | 581 | 98 | $3,879 |
| Montelukast Sodium Generic | 153 | 363 | 51 | $2,012 |
| Azelastine Hcl Generic | 144 | 343 | 85 | $5,895 |
| Ipratropium Bromide Generic | 124 | 205 | 47 | $5,256 |
| Prednisone Generic | 119 | 124 | 65 | $328 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 106 | 122 | 56 | $3,071 |
| Famotidine Generic | 89 | 184 | 40 | $1,117 |
| Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 | 89 | 89 | Under 11 | $485K |
| Epinephrine Generic | 86 | 88 | 76 | $16K |
| Dupixent Syringe Dupilumab | 68 | 68 | 11 | $291K |
| Fluticasone Propionate Generic | 59 | 115 | 28 | $1,419 |
| Azithromycin Generic | 57 | 63 | 40 | $294 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 52 | 75 | 20 | $46K |
| Breo Ellipta Fluticasone/Vilanterol | 48 | 78 | 11 | $30K |
| Triamcinolone Acetonide Generic | 46 | 57 | 26 | $639 |
Brand drugs: 746 claims; generic drugs: 1,630 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sam R Shimamoto $2,437 ($2,437 in general payments such as food, travel and fees) from 27 companies. The largest payer was Genzyme Corporation with $257.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 7 | $257 |
| GlaxoSmithKline, LLC. GSK | 15 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 14 | $240 |
| Genentech USA, Inc. ROG.SW | 6 | $157 |
| Amgen Inc. AMGN | 6 | $145 |
| Grifols USA, LLC | 9 | $143 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $141 |
| Pharming Healthcare, Inc. | 5 | $123 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $94.99 |
| Genentech, Inc. ROG.SW | 1 | $94.3 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.